Prevention of type 2 diabetes through prediabetes remission without weight loss.
Summary
Post hoc analyses of PLIS, replicated in the US DPP, show that prediabetes remission can occur without weight loss and confers protection against incident T2D. Mechanisms include improved insulin sensitivity, beta-cell function, and increased beta-cell GLP-1 sensitivity, alongside a shift toward subcutaneous rather than visceral fat.
Key Findings
- Prediabetes remission occurred without weight loss and was protective against incident T2D.
- Responders showed improved insulin sensitivity, beta-cell function, and beta-cell GLP-1 sensitivity.
- Adipose tissue redistributed toward subcutaneous depots in responders vs visceral gain in nonresponders.
- Findings were reproduced in the US Diabetes Prevention Program.
Clinical Implications
Prevention programs should incorporate explicit glycemic remission targets and consider therapies that improve insulin sensitivity and beta-cell GLP-1 responsiveness, not solely weight-centric goals. Risk stratification may consider fat distribution changes.
Why It Matters
This challenges the prevailing paradigm that weight loss is the primary driver of diabetes prevention, prioritizing glycemic remission as a target. It introduces mechanistic evidence that could shift guideline emphasis beyond weight loss alone.
Limitations
- Post hoc analysis; not a primary randomized comparison targeting remission without weight loss
- Sample size and duration details not specified in the abstract limit assessment of effect heterogeneity
Future Directions
Prospective trials targeting glycemic remission independent of weight change; elucidation of molecular mediators of adipose redistribution and beta-cell GLP-1 sensitivity; integration into risk-based prevention guidelines.
Study Information
- Study Type
- Cohort
- Research Domain
- Prevention/Pathophysiology
- Evidence Level
- II - Well-designed cohort/secondary analysis of randomized trial data with replication
- Study Design
- OTHER